Latest Insurance News

Freedom Care Group Holdings reports a modest cash increase to $0.5 million but continues to grapple with delayed payments from the NDIA, while exploring options to relist on the ASX.

Freedom Care Group Holdings has revealed ongoing financial distress with key subsidiaries entering liquidation and persistent delays in payments from the NDIA, leaving the company with a diminished cash reserve and a strategic focus on asset sales and cost reduction.

Freedom Care Group Holdings has placed its main operating entity into administration following a sharp decline in cash receipts linked to delayed payments from the NDIA and an ongoing audit. The company’s cash balance dropped significantly, prompting urgent restructuring efforts.

MONEYME has reported a robust second quarter with a 26% increase in its loan book to $1.75 billion and a 19% rise in revenue to $60 million, underpinned by improved credit quality and strategic funding initiatives.

Control Bionics has secured a two-year US distribution agreement with AAC leader PRC-Saltillo to broaden access to its NeuroNode technology, enhancing communication options for users with complex needs.

Cleo Diagnostics has broadened its U.S. market opportunity to around 2 million women annually and is on track to complete its pivotal clinical trial early this year, supported by a $5 million capital raise and regulatory progress.

Doctor Care Anywhere reported steady consultation growth and a third consecutive quarter of positive cashflow in Q4 2025, while advancing digital health pilots and reaffirming ambitious medium-term revenue and profitability goals.

FINEOS Corporation Holdings PLC reports a robust €27.8 million cash balance at the end of 2025, maintaining its FY25 revenue guidance despite seasonal cash flow dips and currency fluctuations.

Aeeris Ltd has reported a profitable second quarter for FY26, with total unadjusted revenue rising 61% year-on-year to $1.54 million and annual recurring revenue climbing 16.5% to nearly $4 million. The company’s operational advances and disciplined cost control underpin a promising path to sustainable profitability.

Emyria Limited has reported strong quarterly revenue growth driven by the expansion of its Empax clinic network across multiple Australian states, supported by a recent $8 million institutional placement to fund its national rollout and workforce expansion.

AUB Group has successfully raised AUD 400 million through an institutional placement to fund its acquisition of Prestige and support future growth. A complementary AUD 40 million Share Purchase Plan will also be offered to eligible shareholders.

Control Bionics has raised $3.8 million to fuel growth, forged a key distribution deal with Tobii, and integrated with Apple’s BCI protocol, while advancing its NeuroStrip and NeuroBounce platforms.